Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Clinical Drug Investigation
Erschienen in: Clinical Drug Investigation 8/2001

01.08.2001 | Review Article

Role of P-Glycoprotein and Organic Anion Transporting Polypeptides in Drug Absorption and Distribution

Focus on H1-Receptor Antagonists

verfasst von: Dr Philip D. Hansten, Rene H. Levy

Erschienen in: Clinical Drug Investigation | Ausgabe 8/2001

Einloggen, um Zugang zu erhalten

Abstract

Traditionally, drug-induced changes in cytochrome P450 isoenzyme activity, causing changes in drug metabolism and bioavailability, have been the main focus of drug interaction studies. Recent research, however, suggests that the drug transporters P-glycoprotein and organic anion transporting peptide (OATP), which can effect the efflux and influx of many classes of drugs, may contribute to drug interactions by mechanisms independent of oxidative metabolism. Experimental models designed to selectively probe the function of P-glycoprotein or OATP have demonstrated that changes in the activities of these transporters may have a significant effect on the bioavailability of clinically important drugs, leading to the potential for adverse drug interactions.
This review focuses on what is known about the P-glycoprotein and OATP drug transporters and their effects on drug bioavailability. Where possible, it uses as examples the second-generation Hi-receptor antagonists, where concomitant administration of other drugs or food constituents has been shown to alter the bioavailability of some agents of this class via mechanisms probably mediated by P-glycoprotein and/or OATP.
Literatur
1.
Schoenwetter WF. Allergic rhinitis: Epidemiology and natural history. Allergy Asthma Proc 2000; 21: 1–6PubMedCrossRef
2.
Honig PK, Woosley RL, Zamani K, et al. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992; 52: 231–8PubMedCrossRef
3.
Monahan BP, Ferguson CL, Killeavy ES, et al. Torsades de pointes occurring in association with terfenadine use. JAMA 1990; 264: 2788–90PubMedCrossRef
4.
Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998; 18: 84–112PubMed
5.
6.
Banfield C, Cayen M, Gupta S, et al. Grapefruit juice has no effect on the bioavailability of desloratadine, but reduces the Cmax and AUC of fexofenadine by 30% [abstract]. Ann Allergy Asthma Immunol 2001; 86: 108
7.
8.
Kullak-Ublick GA, Ismair MG, Stieger B, et al. Organic aniontransporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterol 2001; 120: 525–33CrossRef
9.
Kullak-Ublick GA, Hagenbuch B, Stieger B, et al. Functional characterization of the basolateral rat liver organic anion transporting polypeptide. Hepatology 1994; 20: 411–6PubMed
10.
Kim RB, Wandel C, Leake B, et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 1999; 16: 408–14PubMedCrossRef
11.
Silverman JA. P-glycoprotein. Metabolic drug interactions. Philadelphia: Lippincott Williams & Wilkins, 2000: 135–44
12.
Fromm MF. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Phannacol Ther 2000; 38: 69–74
13.
Ueda K, Pastan I, Gottesman MM. Isolation and sequence of the promoter region of the human multidrug-resistance (P-glycoprotein) gene. J Biol Chem 1987; 262: 17432–6PubMed
14.
Thiebaut F, Tsuruo T, Hamada H, et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84: 7735–8PubMedCrossRef
15.
Schinkel AH, Wagenaar E, Mol CA, et al. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996; 97: 2517–4PubMedCrossRef
16.
Dresser GK, Scharwz U, Leake B, et al. Grapefruit juice selectively inhibits OATP not P-glycoprotein [abstract]. Drug Metab Rev 2000; 32Suppl. 2: 193
17.
Mayer U, Wagenaar E, Dorobek B, et al. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J Clin Invest 1997; 100: 2430–6PubMedCrossRef
18.
Golden PL, Pardridge WM. Brain microvascular P-glycoprotein and a revised model of multidrug resistance in brain. Cell Mol Neurobiol 2000; 20: 165–81PubMedCrossRef
19.
Borst P, Zelcer N, van Helvoort A. ABC transporters in lipid transport. Biochim Biophys Acta 2000; 1486: 128–44PubMedCrossRef
20.
Sawamoto T, Van Gelder T, Christians U, et al. Membrane transport of mycophenolate mofetil and its active metabolite, mycophenolic acid in MDCK and MDR1-MDCK cell monolayers [abstract]. J Heart Lung Transplant 2001; 20: 234–5PubMedCrossRef
21.
Cvetkovic M, Leake B, Fromm MF, et al. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 1999; 27: 866–71PubMed
22.
Ishikawa M, Fujita R, Takayanagi M, et al. Reversal of acquired resistance to doxorubicin in K562 human leukemia cells by astemizole. Biol Pharm Bull 2000; 23: 112–5PubMedCrossRef
23.
Wang EJ, Casciano CN, Clement RP, et al. Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein. Drug Metab Dispos 2001; 29: 1080–3PubMed
24.
Kim RB, Fromm MF, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HTV-1 protease inhibitors. J Clin Invest 1998; 101: 289–94PubMedCrossRef
25.
Lee CG, Gottesman MM, Cardarelli CO, et al. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 1998; 37: 3594–601PubMedCrossRef
26.
Alsenz J, Steffen H, Alex R. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers [published erratum appears in Pharm Res 1998 Jun; 15 (6): 958]. Pharm Res 1998; 15: 423–8PubMedCrossRef
27.
Sparreboom A, van Asperen J, Mayer U, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 1997; 94: 2031–5PubMedCrossRef
28.
Mayer U, Wagenaar E, Beijnen JH, et al. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein. Br J Phannacol 1996; 119: 1038–44CrossRef
29.
Lown KS, Mayo RR, Leichtman AB, et al. Role of intestinal P-glycoprotein (mdrl) in interpatient variation in the oral bioavailability of cyclosporine. Clin Phannacol Ther 1997; 62: 248–60CrossRef
30.
Greiner B, Eichelbaum M, Fritz P, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999; 104: 147–53PubMedCrossRef
31.
Schwarz UI, Gramatte T, Krappweis J, et al. P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. Int J Clin Pharmacol Ther 2000; 38: 161–7PubMed
32.
Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 1996; 49: 311–8PubMed
33.
Johne A, Brockmoller J, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St John’s wort (Hypericum perfonitum). Clin Pharmacol Ther 1999; 66: 338–45PubMedCrossRef
34.
Dresser GK, Schwarz UI, Wilkinson GR, et al. St. John’s wort induces intestinal and hepatic CYP3A4 and P-glycoprotein in healthy volunteers [abstract]. Clin Pharmacol Ther 2001; 69:23
35.
Harnman MA, Wang Z, Honig P, et al. Effects of acute and chronic Saint John’s wort (SJW) administration of fexofenadine (FEX) disposition [abstract]. Clin Pharmacol Ther 2001; 69: 53
36.
Jacquemin E, Hagenbuch B, Stieger B, et al. Expression cloning of a rat liver Na(+)-independent organic anion transporter. Proc Natl Acad Sci USA 1994; 91: 133–7PubMedCrossRef
37.
Noe B, Hagenbuch B, Stieger B, et al. Isolation of a multi-specific organic anion and cardiac glycoside transporter from rat brain. Proc Natl Acad Sci USA 1997; 94: 10346–50PubMedCrossRef
38.
Ishizuka H, Konno K, Naganuma H, et al. Transport of temo-caprilat into rat hepatocytes: role of organic anion transporting polypeptide. J Pharmacol Exp Ther 1998; 287: 37–42PubMed
39.
Pang KS, Wang PJ, Chung AY, et al. The modified dipeptide, enalapril, an angiotensin-converting enzyme inhibitor, is transported by the rat liver organic anion transport protein. Hepatology 1998; 28: 1341–6PubMedCrossRef
40.
Shi X, Bai S, Ford AC, et al. Stable inducible expression of a functional rat liver organic anion transport protein in HeLa cells. J Biol Chem 1995; 270: 25591–5PubMedCrossRef
41.
Kullak-Ublick GA, Hagenbuch B, Stieger B, et al. Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterol 1995; 109: 1274–82CrossRef
42.
Bergwerk AJ, Shi X, Ford AC, et al. Immunologie distribution of an organic anion transport protein in rat liver and kidney. Am J Physiol 1996; 271: G231–8PubMed
43.
Angeletti RH, Novikoff PM, Juvvadi SR, et al. The choroid plexus epithelium is the site of the organic anion transport protein in the brain. Proc Natl Acad Sci USA 1997; 94: 283–6PubMedCrossRef
44.
Eckhardt U, Horz JA, Petzinger E, et al. The peptide-based thrombin inhibitor CRC 220 is a new substrate of the basolateral rat liver organic anion-transporting polypeptide. Hepatology 1996; 24: 380–4PubMedCrossRef
45.
Bossuyt X, Muller M, Hagenbuch B, et al. Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. J Pharmacol Exp Ther 1996; 276: 891–6PubMed
46.
Kanai N, Lu R, Bao Y, et al. Estradiol 17-beta-D-glucuronide is a high-affinity substrate for oatp organic anion transporter. Am J Physiol 1996; 270: F326–31PubMed
47.
Satlin LM, Amin V, Wolkoff AW. Organic anion transporting polypeptide mediates organic anion/HCO3 − exchange. J Biol Chem 1997; 272: 26340–5PubMedCrossRef
48.
Reichel C, Gao B, Van Montfoort J, et al. Localization and function of the organic anion-transporting polypeptide Oatp2 in rat liver. Gastroenterol 1999; 117: 688–95CrossRef
49.
Tokui T, Nakai D, Nakagomi R, et al. Pravastatin, an HMG-CoA reductase inhibitor, is transported by rat organic anion transporting polypeptide, oatp2. Pharm Res 1999; 16: 904–8PubMedCrossRef
50.
Kakyo M, Sakagami H, Nishio T, et al. Immunohistochemical distribution and functional characterization of an organic anion transporting polypeptide 2 (oatp2). FEBS Lett 1999; 445: 343–6PubMedCrossRef
51.
Dresser GK, Schwarz UI, Leake B, et al. Citrus juices are potent inhibitors of intestinal OATP but not P-glycoprotein [abstract]. Clin Pharmacol Ther 2001; 69: 23
52.
Bailey DG, Dresser GK, Munoz C, et al. Reduction of fexofenadine bioavailability by fruit juices [abstract]. Clin Pharmacol Ther 2001; 69: 21
53.
Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000; 38: 41–57PubMedCrossRef
54.
Kim AE, Dintaman JM, Waddell DS, et al. Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J Pharmacol Exp Ther 1998; 286: 1439–45PubMed
55.
Hofsli E, Nissen-Meyer J. Effect of erythromycin and tumour necrosis factor on the drug resistance of multidrug-resistant cells: reversal of drug resistance by erythromycin. Int J Cancer 1989; 43: 520–5PubMedCrossRef
56.
Barbey JT, Anderson M, Ciprandi G, et al. Cardiovascular safety of second-generation antihistamines. Am J Rhinol 1999; 13: 235–43PubMedCrossRef
57.
Kreutner W, Hey JA, Anthes J, et al. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 1st communication: receptor selectivity, antihistaminic activity, and antiallergenic effects. Arzneimittelforschung 2000; 50: 345–52PubMed
58.
Kreutner W, Hey JA, Chiu P, et al. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist: 2nd communication: Lack of central nervous system and cardiovascular effects. Arzneimittelforschung 2000; 50: 441–8PubMed
59.
Glue P, Banfield C, Affrime MB, et al. Lack of electrocardiographic interaction between desloratadine and erythromycin [abstract]. Allergy 2000; 55(Suppl. 63): 276
60.
Affrime MB, Banfield C, Glue P, et al. Lack of electrocardiographic effects when desloratadine and ketoconazole are coadministered [abstract]. Allergy 2000; 55Suppl. 63: 277
Metadaten
Titel
Role of P-Glycoprotein and Organic Anion Transporting Polypeptides in Drug Absorption and Distribution
Focus on H1-Receptor Antagonists
verfasst von
Dr Philip D. Hansten
Rene H. Levy
Publikationsdatum
01.08.2001
Verlag
Springer International Publishing
Erschienen in
Clinical Drug Investigation / Ausgabe 8/2001
Print ISSN: 1173-2563
Elektronische ISSN: 1179-1918
DOI
https://doi.org/10.2165/00044011-200121080-00008

Weitere Artikel der Ausgabe 8/2001

Clinical Drug Investigation 8/2001 Zur Ausgabe

Clinical Use

Efficacy of Loratadine Compared with Fexofenadine or Placebo for the Treatment of Seasonal Allergic Rhinitis

Clinical Use

Effects of Administration of Glycoprotein IIb/IIIa Receptor Antagonists in Patients with Failed Thrombolysis

Clinical Use

Comparative Tolerability of Intravenous Azithromycin, Clarithromycin and Erythromycin in Healthy Volunteers

Clinical Use

Mefloquine versus Proguanil in Short-Term Malaria Chemoprophylaxis in Sickle Cell Anaemia

Clinical Pharmacokinetics

Comparison of Oral and Oral Sustained-Release Rilmenidine in Healthy Volunteers and Correlation with In Vitro Sustained-Release Properties

Clinical Use

Randomised, Double-Blind, Placebo-Controlled Study on the Efficacy and Tolerance of Trospium Chloride in Patients with Motor Urge Incontinence